In May 2018, the NF community gathered in Atlanta, GA for a long weekend of patient engagement training, leadership training, research updates, and patient and family support. We asked two first-time attendees to reflect on their experience.
Today, the U.S. House of Representatives Committee on Appropriations approved the FY 2019 Department of Defense Appropriations Bill, which includes $15 million in funding for Neurofibromatosis (NF) research.
Study Shows that Drug Combination Therapies Effective in Treating Schwannomas and Meningiomas
The Synodos for NF2 consortium of the Children’s Tumor Foundation (CTF) today published its first set of results and released its second set of data in the leading scientific journal PLOS ONE.
The Children’s Tumor Foundation (CTF), the largest non-governmental funder of neurofibromatosis (NF) research, and PLOS ONE, a leading peer-reviewed scientific journal, are pleased to announce the successful completion of the first funding cycle of the Drug Discovery Initiative Registered Report (DDIRR) 2017 Awards, a funder-publisher partnership integrating the Registered Reports model into the grant application process.
By Salvatore La Rosa, VP Research and Development
Early investments from the Children’s Tumor Foundation are paying off and delivering innovative and impactful research. It’s great to see research moving forward thanks to the support of both private and public funding. Our philosophy of betting on high-risk high-reward projects is proving successful and will eventually help us realize our vision of ending NF.